(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

Trial Profile

(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms OSKIRA-X
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jun 2012 Additional trial locations (Colombia, Turkey) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top